Clinical trial
Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis
NCT00220779 is registered in ClinicalTrials.gov with Grifols Therapeutics LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis
- Lead sponsor
- Grifols Therapeutics LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2002
- Completion date
- February 28, 2005
- Enrollment
- 128 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.